Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2011-11-30
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Baroreflex Activation Therapy in Patients With Advanced Heart Failure
NCT03230643
Baroreflex Activation Therapy for Heart Failure
NCT02627196
BAROSTIM NEO System in the Treatment of Heart Failure
NCT01471860
Rheos® Diastolic Heart Failure Trial
NCT00718939
BAROSTIM® Hope for Heart Failure Study
NCT01720160
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Device group
Barostim Neo system
Barostim Neo System
Baroreflex Activation Therapy using the Barostim Neo System
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Barostim Neo System
Baroreflex Activation Therapy using the Barostim Neo System
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptomatic heart failure despite optimal, stable pharmacological therapy for at least 4 weeks
Exclusion Criteria
* Known or suspected baroreflex failure or autonomic neuropathy
* Myocardial infarction, unstable angina, syncope, cerebral vascular accident, SCD, or received defibrillation therapy within the past 3 months
* Heart failure secondary to a reversible condition
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CVRx, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edoardo G Gronda, MD, FESC
Role: PRINCIPAL_INVESTIGATOR
MultiMedica
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MultiMedica
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
360025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.